A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

200/25 mg fixed-dose combination (FDC) tablet administered orally

200/10 mg FDC tablet administered orally

120/15 mg FDC tablet administered orally

60/7.5 mg tablet for oral suspension (TOS) administered orally

30/3.75 mg TOS administered orally

15/1.88 mg TOS administered orally

150/150/200/10 mg tablet administered orally

90/90/120/6 mg tablet administered orally

150 mg tablet administered orally

90 mg tablet administered orally

30 mg TOS administered orally

50/200/25 mg FDC tablet administered orally

30/120/15 mg FDC tablet administered orally

15/60/7.52 mg TOS administered orally

7.5/30/3.76 mg TOS administered orally

3.76/15/1.88 mg TOS administered orally

A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country

NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)

Administered according to the prescribing information

Administered according to the prescribing information

Administered according to the prescribing information